drugset / Trial / NCT02130167

Low Concentration Atropine for Myopia Progression in School Children

NCT02130167

Completed 60 enrolled Chang Gung Memorial Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. Recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. The aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

Timeline

Start
2012-08
Primary completion
2017-07
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.01 % Other
Subject Atropine Other / unclassified 0.05 % Other

Indications